Market Cap | 13.92M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -3.63M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 20.00% |
Sales | 2.09M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 11.36 | EPS next 5Y | - | 52W High Chg | -48.00% |
Recommedations | - | Quick Ratio | 1.02 | Shares Outstanding | 111.86M | 52W Low Chg | 79.00% |
Insider Own | 40.45% | ROA | -145.82% | Shares Float | 66.61M | Beta | 0.05 |
Inst Own | - | ROE | - | Shares Shorted/Prior | 222.97K/254.80K | Price | 0.13 |
Gross Margin | 57.29% | Profit Margin | -173.41% | Avg. Volume | 32,641 | Target Price | - |
Oper. Margin | -185.26% | Earnings Date | Oct 28 | Volume | 72,264 | Change | 5.93% |
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Zacks Investment Research | Neutral | Dec 13, 12 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Blotner Bernard | Director Director | Mar 21 | Buy | 0.1299 | 10,000 | 1,299 | 10,000 | 03/22/23 |
BARTLETT ROBERT F | CEO CEO | Mar 22 | Buy | 0.155 | 50,000 | 7,750 | 50,000 | 03/22/23 |
Lee Tom Y | Chief Executive Offi.. Chief Executive Officer | Dec 15 | Buy | 0.131 | 50,000 | 6,550 | 5,001,843 | 12/19/22 |
Lee Tom Y | Chief Executive Offi.. Chief Executive Officer | Mar 16 | Buy | 0.19 | 219,477 | 41,701 | 4,951,843 | 03/22/22 |
Lee Tom Y | Chief Executive Offi.. Chief Executive Officer | Dec 28 | Buy | 0.66 | 78,721 | 51,956 | 4,696,368 | 12/28/20 |